Generate Biomedicines (NASDAQ:GENB) Trading Up 8.1% – Should You Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price rose 8.1% during trading on Monday . The company traded as high as $14.12 and last traded at $14.2090. Approximately 77,430 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 476,821 shares. The stock had previously closed at $13.15.

Wall Street Analyst Weigh In

Several brokerages have weighed in on GENB. Piper Sandler began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price objective for the company. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating on the stock. The Goldman Sachs Group assumed coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target on the stock. Zacks Research raised Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Finally, Guggenheim initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued a “buy” rating and a $30.00 price objective on the stock. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Generate Biomedicines has a consensus rating of “Moderate Buy” and an average target price of $23.20.

Generate Biomedicines Price Performance

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.